IPO - Profile


We are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue.

Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a functional bridge between these two systems to impact tumor killing. Furthermore, they are More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$10.00 4,000,000 Positive High 37.87%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • CohnReznick LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 22 Jul, 2021

Offer 30 Jul, 2021

Look Ahead

Lock Up Expiry Jan 30, 2022

IPO Terms

Offer Price $10.00
Offer Size 4M

Market Sentiments

Stock Price